Search
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalRUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on Ma...
Ranitidine
go.drugbank.com/drugs/DB00863ApprovedWithdrawnRanitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. … [A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … While systemic corticosteroids and other immunosuppressive agents are commonly used as first-line treatments to manage aGvHD, about 30-50% of patients with aGvHD experience inadequately control of disease
Ivermectin
go.drugbank.com/drugs/DB00602ApprovedInvestigationalVet approvedas extreme terminal digit bias and the duplication of blocks of patient records. … [L36763,A238929] In addition, the use of aggregate patient data in large-scale meta-analyses (as opposed to individual patient data (IPD)) has been shown to disguise otherwise blatant data errors, such
Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigationalOsilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery
Furosemide
go.drugbank.com/drugs/DB00695ApprovedInvestigationalVet approved[L7958] Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalAs such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.